Cargando…

Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine

Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promi...

Descripción completa

Detalles Bibliográficos
Autores principales: Desfontaine, Vincent, Guinchard, Sylvie, Marques, Sara, Vocat, Anthony, Moulfi, Farizade, Versace, François, Huser-Pitteloud, Jeff, Ivanyuk, Anton, Bardinet, Carine, Makarov, Vadim, Ryabova, Olga, André, Pascal, Prod'Hom, Sylvain, Chtioui, Haithem, Buclin, Thierry, Cole, Stewart T., Decosterd, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883661/
https://www.ncbi.nlm.nih.gov/pubmed/36563654
http://dx.doi.org/10.1016/j.jchromb.2022.123555
_version_ 1784879552511606784
author Desfontaine, Vincent
Guinchard, Sylvie
Marques, Sara
Vocat, Anthony
Moulfi, Farizade
Versace, François
Huser-Pitteloud, Jeff
Ivanyuk, Anton
Bardinet, Carine
Makarov, Vadim
Ryabova, Olga
André, Pascal
Prod'Hom, Sylvain
Chtioui, Haithem
Buclin, Thierry
Cole, Stewart T.
Decosterd, Laurent
author_facet Desfontaine, Vincent
Guinchard, Sylvie
Marques, Sara
Vocat, Anthony
Moulfi, Farizade
Versace, François
Huser-Pitteloud, Jeff
Ivanyuk, Anton
Bardinet, Carine
Makarov, Vadim
Ryabova, Olga
André, Pascal
Prod'Hom, Sylvain
Chtioui, Haithem
Buclin, Thierry
Cole, Stewart T.
Decosterd, Laurent
author_sort Desfontaine, Vincent
collection PubMed
description Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promising candidates, showing extraordinary potency in vitro and in murine models against drug-susceptible and drug-resistant Mycobacterium tuberculosis. A previous analytical method using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed by our group to support phase I clinical trials of PBTZ169. These plasma sample analyses revealed the presence of several additional metabolites among which the most prominent was H(2)PBTZ, a reduced species obtained by dearomatization of macozinone, one of the first examples of Meisenheimer Complex (MC) metabolites identified in mammals. Identification of these new metabolites required the optimization of our original method for enhancing the selectivity between isobaric metabolites as well as for ensuring optimal stability for H(2)PBTZ analyses. Sample preparation methods were also developed for plasma and urine, followed by extensive quantitative validation in accordance with international bioanalytical method recommendations, which include selectivity, linearity, qualitative and quantitative matrix effect, trueness, precision and the establishment of accuracy profiles using β-expectation tolerance intervals for known and newer analytes. The newly optimized methods have been applied in a subsequent Phase Ib clinical trial conducted in our University Hospital with healthy subjects. H(2)PBTZ was found to be the most abundant species circulating in plasma, underscoring the importance of measuring accurately and precisely this unprecedented metabolite. Low concentrations were found in urine for all monitored analytes, suggesting extensive metabolism before renal excretion.
format Online
Article
Text
id pubmed-9883661
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98836612023-01-31 Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine Desfontaine, Vincent Guinchard, Sylvie Marques, Sara Vocat, Anthony Moulfi, Farizade Versace, François Huser-Pitteloud, Jeff Ivanyuk, Anton Bardinet, Carine Makarov, Vadim Ryabova, Olga André, Pascal Prod'Hom, Sylvain Chtioui, Haithem Buclin, Thierry Cole, Stewart T. Decosterd, Laurent J Chromatogr B Analyt Technol Biomed Life Sci Article Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promising candidates, showing extraordinary potency in vitro and in murine models against drug-susceptible and drug-resistant Mycobacterium tuberculosis. A previous analytical method using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed by our group to support phase I clinical trials of PBTZ169. These plasma sample analyses revealed the presence of several additional metabolites among which the most prominent was H(2)PBTZ, a reduced species obtained by dearomatization of macozinone, one of the first examples of Meisenheimer Complex (MC) metabolites identified in mammals. Identification of these new metabolites required the optimization of our original method for enhancing the selectivity between isobaric metabolites as well as for ensuring optimal stability for H(2)PBTZ analyses. Sample preparation methods were also developed for plasma and urine, followed by extensive quantitative validation in accordance with international bioanalytical method recommendations, which include selectivity, linearity, qualitative and quantitative matrix effect, trueness, precision and the establishment of accuracy profiles using β-expectation tolerance intervals for known and newer analytes. The newly optimized methods have been applied in a subsequent Phase Ib clinical trial conducted in our University Hospital with healthy subjects. H(2)PBTZ was found to be the most abundant species circulating in plasma, underscoring the importance of measuring accurately and precisely this unprecedented metabolite. Low concentrations were found in urine for all monitored analytes, suggesting extensive metabolism before renal excretion. Elsevier 2023-01-15 /pmc/articles/PMC9883661/ /pubmed/36563654 http://dx.doi.org/10.1016/j.jchromb.2022.123555 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Desfontaine, Vincent
Guinchard, Sylvie
Marques, Sara
Vocat, Anthony
Moulfi, Farizade
Versace, François
Huser-Pitteloud, Jeff
Ivanyuk, Anton
Bardinet, Carine
Makarov, Vadim
Ryabova, Olga
André, Pascal
Prod'Hom, Sylvain
Chtioui, Haithem
Buclin, Thierry
Cole, Stewart T.
Decosterd, Laurent
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title_full Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title_fullStr Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title_full_unstemmed Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title_short Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
title_sort optimized lc-ms/ms quantification of tuberculosis drug candidate macozinone (pbtz169), its dearomatized meisenheimer complex and other metabolites, in human plasma and urine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883661/
https://www.ncbi.nlm.nih.gov/pubmed/36563654
http://dx.doi.org/10.1016/j.jchromb.2022.123555
work_keys_str_mv AT desfontainevincent optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT guinchardsylvie optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT marquessara optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT vocatanthony optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT moulfifarizade optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT versacefrancois optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT huserpitteloudjeff optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT ivanyukanton optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT bardinetcarine optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT makarovvadim optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT ryabovaolga optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT andrepascal optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT prodhomsylvain optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT chtiouihaithem optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT buclinthierry optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT colestewartt optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine
AT decosterdlaurent optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine